Proposes Change of Business to a mining/investment issuerAdds renowned geologist Dr. Quinton Hennigh as Investment AdvisorMr. Kevin Ramsay, CPA, CA, will join the Board of DirectorsAnnual General and Special Meeting to be held on February 24, 2026Shareholders are encouraged to visit www.TheFutureofLAB.com to stay up to date TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) announces that having completed an extensive evaluation ...

Core Insights - Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a quiet news cycle [1] Company Summaries - Modular Medical, Inc. (MODD) shares increased by 11.51% to $0.4380 after a previous decline of 1.80% at the close, following the IRB approval for its Pivot insulin delivery system study announced on November 17 [2] - Standard BioTools Inc. (LAB) saw a 4.90% rise to $1.50 after a 0.70% gain during regular trading, following a strategic collaboration with Molecular Instruments announced on November 19 [3] - Werewolf Therapeutics, Inc. (HOWL) rose 4.39% to $1.0199 after a strong 7.33% gain during regular trading, reflecting continued investor optimism despite no new updates [4] - Cogent Biosciences, Inc. (COGT) climbed 6.09% to $42.85 in after-hours trading, building on a 1.69% rise during regular trading, indicating strong investor confidence in its pipeline [5] - Longeveron Inc. (LGVN) shares increased by 4.59% to $0.6772, extending gains from a 7.02% rise during regular trading, with upcoming presentation of Alzheimer's study results at CTAD 2025 highlighting ongoing research [6] - AbCellera Biologics Inc. (ABCL) gained 3.85% to $3.78 after a 0.55% increase during regular trading, reflecting renewed investor interest in its antibody discovery platform [7]

Core Insights - Molecular Instruments and Standard BioTools have announced a strategic collaboration to enhance Imaging Mass Cytometry (IMC) workflows using HCR imaging technologies, specifically the HCR HiFi Encoder for protein imaging with any primary antibody [1][4][5] Group 1: Collaboration Details - The partnership aims to create a unified platform for high-fidelity multi-omic analysis of RNA and protein targets in complex tissues, enabling amplified detection through HCR Gold and direct protein encoding via the HCR HiFi Encoder [2][4] - This collaboration integrates HCR Gold for RNA and protein imaging with the Hyperion Imaging System, marking the first time amplified detection for both RNA and protein is introduced in IMC technology [3][4] Group 2: Technological Advancements - The integration of HCR amplification with the Hyperion platform is expected to increase sensitivity, enhance flexibility, and accelerate the path from discovery to clinical translation [5] - The collaboration allows researchers to utilize their own primary antibodies in a simplified workflow while achieving robust visualization of low-abundance markers, significantly improving the sensitivity and flexibility of IMC spatial biology workflows [3][4] Group 3: Future Developments - Joint development activities are currently underway, with early-access opportunities available for interested collaborators [6]

Core Insights - Several small-cap healthcare and biotech companies experienced significant price increases in after-hours trading following earnings updates or upcoming financial disclosures [1] Company Summaries - MacroGenics, Inc. (MGNX) saw a 10.2% rise to $1.62 after hours, recovering from a 3.29% decline during the regular session. The company reported a third-quarter net income of $16.8 million, or $0.27 per share, down from $56.3 million, or $0.90 per share, year-over-year. Revenue fell to $72.8 million from $110.7 million [2] - SELLAS Life Sciences Group, Inc. (SLS) advanced 9.4% to $1.63 in after-hours trading. The company narrowed its quarterly net loss to $6.8 million, or $0.06 per share, compared to $7.1 million, or $0.10 per share, in the prior-year quarter. As of September 30, 2025, SELLAS reported cash and equivalents of approximately $44.3 million [3] - Standard BioTools Inc. (LAB) increased by 4.24% to $1.23 after hours, despite no official press releases or updates on Wednesday. The stock had closed slightly lower during the regular session [4] - KORU Medical Systems, Inc. (KRMD) gained 8.47% to $4.10 after hours, following a 1.34% increase earlier in the day. The company reported a narrower net loss of $0.8 million for the third quarter, compared to $1.6 million in the prior-year period. Revenue rose 27.2% to $10.4 million. KORU also raised its full-year revenue guidance to a range of $40.5 million - $41.0 million and reaffirmed its gross margin outlook of 61%-63% [5] - Hyperfine, Inc. (HYPR) climbed 8.18% to $1.19 after hours. No new announcements were made on Wednesday, but the company is scheduled to release its third-quarter results on Thursday, with analysts anticipating a loss of $0.10 per share and revenue of $3.52 million [6] - Wave Life Sciences Ltd. (WVE) added 5.68% to reach $7.35 in after-hours trading. The company reported a third-quarter net loss of $53.9 million, an improvement from $61.8 million in the prior-year quarter. Revenue for the period was $7.6 million, compared to a negative revenue figure of ($7.7) million last year [7]

Core Insights - Labrador Gold Corp. is advancing its exploration programs in 2025 at the Hopedale and Borden Lake gold projects, focusing on orogenic gold and other mineral deposits [1][25] - The Hopedale property is situated in the Florence Lake greenstone belt, which is underexplored compared to similar global belts, showing significant gold anomalies [25] - The Borden Lake Extension property is adjacent to Discovery's Borden Gold Mine, with ongoing exploration efforts to identify mineralization [26] Hopedale Project - The 2025 exploration program primarily targets the Thurber Gold trend, a 3-kilometer area with notable gold occurrences [2] - A 26-line kilometer Induced Polarization (IP)/Resistivity survey was conducted, revealing a trend of moderate chargeability and high resistivity linked to significant gold occurrences [3][4] - Detailed mapping and sampling efforts have identified gold grades of 2.2g/t Au and nickel values ranging from 0.15% to 0.25% in various locations [5] Borden Lake Extension - A drone magnetic and LiDAR survey was initiated to better understand the geological contact between different rock types in the Borden Lake Extension [11] - Field crews located 43 outcrops and collected 30 bedrock samples, although no obvious mineralization was found [14] - The magnetic survey identified a significant east-northeast trending lineament, correlating with geological features interpreted from Ontario Geological Survey data [15] Project Acquisition Update - Labrador Gold is actively evaluating resource opportunities in Canada, having reviewed 29 resource projects and 22 pre-resource projects for potential significant resources [19]

Financial Performance - Total revenue for Q3 2025 was $19.552 million, a decrease of 11% from $22.086 million in Q3 2024[16] - Product revenue decreased to $13.800 million in Q3 2025, down 12.5% from $15.779 million in Q3 2024[16] - Gross profit for Q3 2025 was $9.484 million, compared to $12.126 million in Q3 2024, reflecting a decline of 21.5%[16] - The net loss for Q3 2025 was $34.687 million, compared to a net loss of $26.938 million in Q3 2024, representing a 28.5% increase in losses[16] - For the nine months ended September 30, 2025, the net loss was $94,179, compared to a net loss of $104,813 for the same period in 2024, representing a 9% improvement[24] - The Company reported a net loss from continuing operations of $31,684,000 for the three months ended September 30, 2025, compared to a net loss of $21,919,000 for the same period in 2024[103] Operating Expenses - Total operating expenses increased to $42.422 million in Q3 2025, up 9.5% from $38.825 million in Q3 2024[16] - Research and development expenses were $6.356 million in Q3 2025, a decrease of 8.4% from $6.939 million in Q3 2024[16] - Selling, general and administrative expenses rose to $26.595 million in Q3 2025, an increase of 8.7% from $24.466 million in Q3 2024[16] - Stock-based compensation expense for the quarter ending June 30, 2025, amounted to $8.474 million, reflecting an increase from $6.387 million in the previous quarter[20] - Stock-based compensation expense for the three months ended September 30, 2025, totaled $7,536,000, an increase from $4,649,000 in the same period in 2024[97] - The company recognized restructuring charges of approximately $10.8 million for workforce reductions and incurred an additional $2.2 million in facility-related restructuring expenses during the nine months ended September 30, 2025[116] Cash and Assets - Cash and cash equivalents decreased to $129.418 million as of September 30, 2025, down from $166.728 million at the end of 2024[14] - Total current assets increased to $472.439 million as of September 30, 2025, compared to $375.883 million at the end of 2024[14] - The total assets held for sale as of September 30, 2025, amounted to $230.7 million, with total liabilities of $22.2 million[65] - Cash and cash equivalents at the end of the period totaled $132,006, down from $211,938 at the end of the same period in 2024[24] - The fair value of total assets measured at fair value as of September 30, 2025, was $186,544,000, with cash equivalents and short-term investments comprising a significant portion[91] Liabilities and Equity - Total liabilities decreased slightly to $139.977 million as of September 30, 2025, from $140.623 million at the end of 2024[14] - As of September 30, 2025, total stockholders' equity was $399.659 million, with an accumulated deficit of $1,279.83 million[20] - The balance of restructuring liabilities at September 30, 2025, was $6.311 million, reflecting ongoing adjustments from previous restructuring plans[117] Business Operations and Strategy - The company expects the acquisition of SomaLogic and Sengenics to close in the first half of 2026, which will enhance its capabilities in the proteomics sector[32] - The Company completed the merger with SomaLogic on January 5, 2024, with a fair value of consideration transferred amounting to $444.2 million and recognized a gain on bargain purchase of $25.2 million[52] - The Company acquired 100% of Sengenics on November 21, 2024, further expanding its business operations[54] - The divestiture of the SomaScan Business to Illumina is expected to close in the first half of 2026, with an aggregate cash consideration of up to $425 million, including an upfront payment of $350 million[58][60] - The company has classified the results of the SomaScan Business as discontinued operations, impacting its financial reporting[34] Future Outlook - The Company updated its forecast for future sales under the Collaboration Agreement, reducing the transaction price from $158.4 million to $155.5 million due to decreased forecasted royalties[57] - The company expects to recognize $3,964,000 in revenue from unfulfilled performance obligations in the remainder of 2025[70] - The company plans to consolidate its R&D capabilities from South San Francisco to Singapore, with the process expected to be completed by December 31, 2025[113] Market and Economic Conditions - The company does not believe inflation has materially affected its business in the last two years, but anticipates increases in labor and operating costs if global inflation trends continue[184] - The company has not hedged its foreign currency exposure, which could materially affect its financial condition and results of operations[183]

Financial Performance - Total combined company revenue for Q3 2025 was $46.2 million, with revenue from continuing operations at $19.6 million, down 11% year-over-year[6]. - Consumables revenue decreased to $8.7 million, down 17% year-over-year, while instruments revenue was $5.1 million, down 3% year-over-year[8]. - Total revenue for Q3 2025 was $19,552 million, a decrease of 11% compared to $22,086 million in Q3 2024[22]. - Product revenue decreased to $13,800 million in Q3 2025 from $15,779 million in Q3 2024, representing a decline of 12.5%[22]. - Revenue for Q3 2025 was $26,693, an increase of 16% compared to $22,884 in Q3 2024[27]. - Revenue for Q3 2025 was $46,245 million, a 2.8% increase from $44,970 million in Q3 2024[32]. Profitability - The net loss for Q3 2025 was $31.7 million, a 45% increase from the net loss of $21.9 million in Q3 2024[8]. - Adjusted EBITDA for Q3 2025 was a loss of $16.5 million, compared to a loss of $13.7 million in Q3 2024, reflecting a 21% increase in losses[8]. - Net loss from continuing operations for Q3 2025 was $31,684 million, compared to a loss of $21,919 million in Q3 2024, reflecting a 44% increase in losses[22]. - Net loss for Q3 2025 was $34,687 million, compared to a net loss of $26,938 million in Q3 2024, reflecting a 28.5% increase in losses[32]. - Adjusted EBITDA for Q3 2025 was $(16,649) million, compared to $(14,490) million in Q3 2024, indicating a worsening of 14.9%[35]. Expenses - Operating expenses for Q3 2025 were $42.4 million, an increase of 9% compared to Q3 2024, including $9.4 million in restructuring charges[8]. - Total expenses for Q3 2025 were $29,696, compared to $27,903 in Q3 2024, representing a 6.4% increase[27]. - Total expenses for Q3 2025 were $80,932 million, an increase of 12.5% compared to $71,908 million in Q3 2024[32]. - Operating expenses increased to $42,422 million in Q3 2025, compared to $38,825 million in Q3 2024, marking an increase of 4.1%[22]. - Non-GAAP operating expenses for Q3 2025 were $27,004, up from $26,320 in Q3 2024, indicating a 3% increase[24]. - Research and development (R&D) operating expenses for Q3 2025 were $6,356, a decrease of 8.4% from $6,939 in Q3 2024[24]. - Selling, general and administrative (SG&A) operating expenses for Q3 2025 were $21,373, up from $19,932 in Q3 2024, marking a 7.2% increase[24]. - Research and development expenses for Q3 2025 were $11,205 million, down from $13,156 million in Q3 2024, a decrease of 14.8%[34]. - Selling, general and administrative expenses for Q3 2025 were $35,069 million, slightly up from $34,403 million in Q3 2024[34]. - Transaction and integration expenses for Q3 2025 were $2,246 million, significantly lower than $5,079 million in Q3 2024, a decrease of 55.8%[34]. Cash and Assets - Cash and cash equivalents stood at $217.0 million as of September 30, 2025, with an expected increase to approximately $550 million upon closing the Illumina transaction in H1 2026[6]. - Cash and cash equivalents at the end of Q3 2025 were $129,418 million, down from $166,728 million at the end of 2024[18]. - Total current assets increased to $472,439 million as of September 30, 2025, compared to $375,883 million at the end of 2024, an increase of 25.7%[18]. - Total liabilities decreased slightly to $139,977 million as of September 30, 2025, from $140,623 million at the end of 2024[18]. Strategic Initiatives - The company implemented a restructuring plan expected to deliver over $40 million in annualized cost savings, fully realized by 2026[4]. - The operational restructuring plan aims to align resources with long-term strategic objectives and is expected to generate efficiencies across various functions[5]. - Standard BioTools is positioned for strategic M&A to fuel growth and deliver long-term value for shareholders, supported by a strong balance sheet and cash inflow from the Illumina transaction[3].

Core Insights - Standard BioTools Inc. reported financial results for Q3 2025, highlighting a focus on operational efficiency and cost savings initiatives aimed at achieving profitability by 2026 [3][4][7]. Financial Performance - Q3 2025 revenue from continuing operations was $19.6 million, a decrease of 11% year-over-year from $22.1 million in Q3 2024 [6][12]. - Gross margin for Q3 2025 was 48.5%, down from 54.9% in Q3 2024, while non-GAAP gross margin was 53.5%, compared to 57.3% in the same period last year [6][12]. - Operating expenses increased to $42.4 million in Q3 2025, up 9% from $38.8 million in Q3 2024, largely due to restructuring charges [6][12]. - The net loss from continuing operations for Q3 2025 was $31.7 million, compared to a net loss of $21.9 million in Q3 2024, marking a 45% increase in losses [6][12]. Operational Restructuring - The company implemented a phased operational restructuring plan expected to yield over $40 million in annualized cost savings by 2026, including a 20% reduction in workforce [4][5]. - The restructuring aims to enhance operational efficiency and align resources with long-term strategic goals, contributing to a path toward positive adjusted EBITDA in 2026 [4][5]. Cash Position and Future Outlook - As of September 30, 2025, Standard BioTools had $217 million in cash and cash equivalents, with an anticipated increase to approximately $550 million following a pending transaction with Illumina in the first half of 2026 [7][10]. - The company continues to expect full-year 2025 revenue in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million [10]. Market Position and Strategy - Standard BioTools is positioned to expand its portfolio through strategic mergers and acquisitions, leveraging a strong balance sheet and cash reserves to drive growth and deliver long-term shareholder value [3][7].

Group 1 - Standard BioTools Inc. will publish its third quarter 2025 financial results on November 4, 2025, after U.S. market close [1] - The company is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [2] - Standard BioTools utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease [2] Group 2 - The company collaborates with various sectors including academic, government, pharmaceutical, and biotechnology laboratories globally [2] - Focus areas for Standard BioTools include translational and clinical research, particularly in oncology, immunology, and immunotherapy [2]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The H1 2025 financial statements reflect the company's position, operations, and cash flows, with the SomaScan Business reclassified as discontinued, reporting a **$59.5 million** net loss [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to **$557.0 million**, with SomaScan Business assets and liabilities reclassified as 'held for sale' Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $158,617 | $166,728 | | Short-term investments | $78,468 | $126,146 | | Current assets held for sale | $223,089 | $42,963 | | **Total Assets** | **$556,965** | **$612,345** | | **Liabilities** | | | | Total current liabilities | $98,024 | $65,895 | | **Total Liabilities** | **$132,430** | **$140,623** | | **Total Stockholders' Equity** | **$424,535** | **$471,722** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For H1 2025, total revenue from continuing operations decreased to **$42.0 million**, resulting in a total net loss of **$59.5 million** Statement of Operations Summary (Six Months Ended June 30, in thousands) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Total Revenue | $41,984 | $44,145 | | Gross Profit | $21,677 | $21,399 | | Loss from continuing operations | ($52,667) | ($74,705) | | Net loss from continuing operations | ($41,043) | ($41,848) | | Loss from discontinued operations, net of tax | ($18,449) | ($36,027) | | **Net Loss** | **($59,492)** | **($77,875)** | Net Loss Per Share (Six Months Ended June 30) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Net loss per share from continuing operations | ($0.11) | ($0.26) | | Net loss per share from discontinued operations | ($0.05) | ($0.11) | | **Net loss per share attributable to common stockholders** | **($0.16)** | **($0.37)** | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For H1 2025, net cash used in operating activities improved to **$51.0 million**, with overall cash decreasing by **$7.6 million** Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($50,951) | ($101,526) | | Net cash provided by investing activities | $42,130 | $368,331 | | Net cash provided by (used in) financing activities | $62 | ($48,094) | | **Net (decrease) increase in cash** | **($7,614)** | **$218,601** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail significant accounting policies and events, including the SomaScan Business sale to Illumina and its reclassification as discontinued operations - On June 22, 2025, the Company entered into a Stock Purchase Agreement with Illumina to sell its SomaScan Business, which includes SomaLogic and Sengenics[30](index=30&type=chunk) - The SomaScan Business met the criteria for held-for-sale and discontinued operations in Q2 2025, with its results now reported separately for all periods presented[32](index=32&type=chunk) - The company reassessed its operating segments in Q1 2025 and now operates as a single reportable segment, managing the business on a consolidated basis as a multi-omics company[36](index=36&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=31&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, highlighting the SomaScan Business divestiture, a **5%** revenue decrease for continuing operations, and sufficient liquidity of **$237.1 million** [Recent Developments](index=31&type=section&id=Recent%20Developments) The key recent development is the June 22, 2025 agreement to sell the SomaScan Business to Illumina for up to **$425 million** in cash consideration - Standard BioTools agreed to sell its SomaScan Business (SomaLogic and Sengenics subsidiaries) to Illumina[111](index=111&type=chunk) Illumina Transaction Terms | Component | Amount/Details | | :--- | :--- | | Upfront Cash Payment | $350 million | | Earnout Payments | Up to $75 million (based on 2025-2026 revenue targets) | | Additional Consideration | Royalty and license agreements for SOMAmer-based products | | Expected Closing | First half of 2026 | [Results of Operations](index=36&type=section&id=Results%20of%20Operations) For H1 2025, revenue from continuing operations decreased by **5%** to **$42.0 million**, while total operating expenses fell **23%** Revenue from Continuing Operations (Six Months Ended June 30, in thousands) | Category | 2025 | 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Instruments | $11,861 | $11,950 | ($89) | (1)% | | Consumables | $18,593 | $19,258 | ($665) | (3)% | | Services and other | $11,530 | $12,937 | ($1,407) | (11)% | | **Total Revenue** | **$41,984** | **$44,145** | **($2,161)** | **(5)%** | Operating Expenses from Continuing Operations (Six Months Ended June 30, in thousands) | Category | 2025 | 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $11,662 | $14,852 | ($3,190) | (21)% | | Selling, general and administrative | $57,929 | $51,274 | $6,655 | 13% | | Restructuring and related charges | $3,279 | $10,033 | ($6,754) | (67)% | | Transaction and integration expenses | $1,474 | $19,945 | ($18,471) | (93)% | | **Total Operating Expenses** | **$74,344** | **$96,104** | **($21,760)** | **(23)%** | - The loss from discontinued operations decreased by **49%** for the six months ended June 30, 2025, primarily due to cost reductions from restructuring activities completed in 2024[151](index=151&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company had **$237.1 million** in liquidity and an accumulated deficit of **$1.25 billion**, with improved operating cash flow - As of June 30, 2025, the company had **$237.1 million** in cash, cash equivalents, and short-term investments[155](index=155&type=chunk) - The company has an accumulated deficit of **$1.245 billion** as of June 30, 2025, and has historically funded operations through equity offerings, loans, and preferred stock[152](index=152&type=chunk) Cash Flow Summary (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($50,951) | ($101,526) | | Net cash provided by investing activities | $42,130 | $368,331 | | Net cash provided by (used in) financing activities | $62 | ($48,094) | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from interest rates and foreign currency, recognizing a **$5.5 million** foreign currency exchange gain in H1 2025 - Primary market risks include interest rate fluctuations on cash and investments, and foreign currency risk from international operations[166](index=166&type=chunk)[167](index=167&type=chunk)[168](index=168&type=chunk) - The company recognized a **$5.5 million** foreign currency exchange gain in the first six months of 2025 due to favorable rate changes[168](index=168&type=chunk) [Item 4. Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The CEO and CFO concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective at the reasonable assurance level[171](index=171&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, internal controls[172](index=172&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company is subject to various legal proceedings, detailed in Note 6, but does not anticipate a material adverse effect from pending matters - Information regarding legal proceedings is detailed in Note 6 of the financial statements[175](index=175&type=chunk) [Item 1A. Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) Risks relate to the pending SomaScan Business divestiture to Illumina, including transaction consummation, business disruption, and benefit realization - There is no assurance that the proposed sale of the SomaScan Business to Illumina will be consummated, which could adversely affect the company's stock price and business[178](index=178&type=chunk)[179](index=179&type=chunk) - The announcement and pendency of the Illumina transaction could disrupt business by causing employee uncertainty, diverting management attention, and affecting relationships with vendors and suppliers[179](index=179&type=chunk)[181](index=181&type=chunk) - The company may be unable to fully realize the expected benefits, such as substantial operating and capital cost savings, from the transaction[180](index=180&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=48&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales or common stock repurchases occurred under the **$50.0 million** program during the quarter, with **$9.5 million** remaining - No shares of common stock were repurchased during the three months ended June 30, 2025[185](index=185&type=chunk) - As of June 30, 2025, the company has repurchased an aggregate of **$40.5 million** of its common stock under the **$50.0 million** 2024 Share Repurchase Program[185](index=185&type=chunk) [Item 5. Other Information](index=48&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter - No officers or directors adopted, modified, or terminated any 10b5-1 trading arrangements during the quarter[188](index=188&type=chunk)